TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01689025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0006
Description: Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
Study: NCT03397303

Intervention type: OTHER
Group type: OTHER
Intervention: elastography measurements
Description: elastography measurements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: elastography measurements
Description: elastography measurements
Study: NCT01220843

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Description: dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks ( each tablet :800mg sevelamer carbonate
Study: NCT00366288

Intervention type: DRUG
Intervention: PAZ-417
Description: 2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.

Intervention type: DRUG
Intervention: PAZ-417
Description: 2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.

Intervention type: DRUG
Intervention: PAZ-417
Description: 2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.

Intervention type: DRUG
Intervention: PAZ-417
Description: 2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.
Study: NCT02821442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture points selected on the arms and legs using both acupuncture and electroacupuncture to assess effectiveness in alleviating neuropathic pain caused by chemotherapy in breast cancer patients

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Placebo needles appear to penetrate but do not actually penetrate the skin
Study: NCT01340625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone/Ethinyl Estradiol
Description: 0.4 mg/35 mcg Chewable Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovcon® 35 Fe
Description: 0.4 mg/35 mcg Chewable Tablets
Study: NCT00366288

Intervention type: DRUG
Intervention: PAZ-417
Description: 2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.

Intervention type: DRUG
Intervention: PAZ-417
Description: 2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.

Intervention type: DRUG
Intervention: PAZ-417
Description: 2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.
Study: NCT03007160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Citrate Extended-release Tablets
Description: Daily 3.24g, Po ,Tid, each 1.08g/tablets
Study: NCT00905073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporin and methotrexate
Description: cyclosporin 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for one year and methotrexate 5 mg/kg/day for one year. After 6 weeks, cyclosporin doses will adjusted to maintain blood cyclo levels to 100-200 ng/ml.
Study: NCT00691821

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dressings
Description: Participants will receive standard dressings changes as needed. Different dressing types (e.g., silver, simple gauze, hydrogel, foam, creams, gels) will be used dependent on the type of the wound (e.g., dry, wet, and intermediate).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (Vacuum-Assisted Closure System [V.A.C.® Therapy™, KCI Medical Canada Inc., Mississauga, Ontario])
Description: Participants will receive negative pressure wound therapy.
Study: NCT02528071

Intervention type: OTHER
Intervention: Diaphragmatic endurance test
Description: This consists of hyperventilation in a flask while maintaining the constant level of Carbon Dioxide (CO2). The patient will realize hyperventilation to increasing levels of Maximum Minute Ventilation (MMV), corresponding to increasing levels of respiratory rate, until exhaustion

Intervention type: OTHER
Intervention: Diaphragmatic endurance test
Description: This consists of hyperventilation in a flask while maintaining the constant level of Carbon Dioxide (CO2). The patient will realize hyperventilation to increasing levels of Maximum Minute Ventilation (MMV), corresponding to increasing levels of respiratory rate, until exhaustion
Study: NCT00536198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: 50 mg of sertraline will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg of placebo will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg.
Study: NCT04150393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MaaT033 capsule
Description: Oral capsule
Study: NCT02403154

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Internal Fixator
Description: Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal Fixator
Description: Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: External fixator
Description: External fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are outside of the body.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External fixator
Description: External fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are outside of the body.
Study: NCT01656473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MI and DBT
Description: One individual session of Motivational Interview followed by 12 weeks of Dialectical Behaviour Therapy group skills training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MI and DBT
Description: Individual Motivational Interview session plus 12-week Dialectical Behaviour Therapy skills group
Study: NCT04216771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Idarubicin 10mg/m²/day, D1 (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ID cytarabine
Description: Cytarabine 1.5g/m² /12h, D1-D3 (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID cytarabine
Description: Cytarabine 1.5g/m² /12h, D1-D3 (IV)
Study: NCT03577691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training for use of web based Decision Aid
Description: Subjects will be guided during a 30 minutes training session to use the website

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No training for use of web based Decision Aid
Description: Subjects will not be guided during a 30 minutes training session to use the website

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pretest surveys and posttest surveys
Description: Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pre test and posttest surveys or only posttest surveys that will take 15 mts of time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pretest surveys and posttest surveys
Description: Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pre test and posttest surveys or only posttest surveys that will take 15 mts of time

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Only posttest surveys
Description: Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pretest and posttest surveys or only posttest surveys.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Only posttest surveys
Description: Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pretest and posttest surveys or only posttest surveys.
Study: NCT04368767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin-to-skin
Description: Skin-to-skin contact will be performed for two hours daily for three consecutive days in the first week of life, usually in the afternoon. This time interval will allow all pre-intervention sample collection to begin 1 hour after the infant's feeding schedule in the afternoon. After pre-intervention measures of axillary temperature, heart rate, respiratory rate, and oxygen saturation by pulse oximetry (SPO2) are obtained; cotton balls placed in the diaper for urine collection will be removed and stored in an appropriate container. Salivary oxytocin and cortisol will be collected per protocol below. Mothers will be requested to sit in reclining chairs with a front opened blouse or hospital gown. Infants will be removed from the incubator and placed naked except for a diaper and hat directly onto the skin between the mother's breasts and covered with a blanket. All infants will be monitored. After the two hours of SSC is completed, the infant will be returned to the incubator.
Study: NCT04103853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proxalutamide
Description: Stage1:Dose esclation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.
Study: NCT01250834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered subcutaneously.
Study: NCT04086862

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic ultrasound
Description: A commercially available ultrasound machine will provide 5 minutes of ultrasound at 0.4 watt/cm\^2 and 100% duty cycle sequentially to each masseter muscle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Description: A commercially available ultrasound machine will provide 5 minutes of ultrasound at 0.4 watt/cm\^2 and 100% duty cycle sequentially to each masseter muscle.
Study: NCT04531293

Intervention type: DEVICE
Group type: OTHER
Intervention: Respiratory Analysis System
Description: Measurement of total lung capacity using total-breath method

Intervention type: DEVICE
Group type: OTHER
Intervention: Respiratory Analysis System
Description: Measurement of total lung capacity using total-breath method

Intervention type: DEVICE
Group type: OTHER
Intervention: Respiratory Analysis System
Description: Measurement of total lung capacity using standard method

Intervention type: DEVICE
Group type: OTHER
Intervention: Respiratory Analysis System
Description: Measurement of total lung capacity using standard method
Study: NCT03477877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indashyikirwa Couples Training
Description: A training curriculum for heterosexual couples in Rwanda comprising 20 3-hour modules (60 hours total) delivered to groups of 15 couples (30 people). Each module facilitated by male and 1 female facilitator. Curriculum topics include: types and uses of personal and interpersonal power (power within, power over, power with, power to), gender, gender based violence, triggers for intimate partner violence, conflict management, economic development, sexuality, alcohol, social norms and community change. Delivered by RWAMREC.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indashyikirwa Activist Training
Description: This training is offered to a subset of individuals who complete the couples curriculum (randomly selected from among those who are are willing and eligible). These individuals are trained to serve as community activists, teach peers about the types of power (power within, power over, power with, power to), and advocate for community change to prevent intimate partner violence. Delivered by RWAMREC.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indashyikirwa Opinion Leader Training
Description: Training delivered to opinion leaders (political office holders, religious leaders, service providers), in intervention communities. Training comprised 8 x 3 hour sessions (24 hours) delivered for groups of up to 40 participants. Introduces Opinion Leaders to the concepts of power (power within, power over, power with, power to) and to essential concepts around women's legal rights. Delivered by Rwanda Women's Network.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indashyikirwa Women's Spaces
Description: Establishment of 1 Women's Space per intervention sector -- a physical space with trained facilitators on duty from which support and referrals for women experiencing IPV could be offered and ad hoc programming responsive to community needs and interest can be run. Typical activities include once-off open trainings for community members on the concepts of power (power within, power over, power with, power to), essential concepts around women's legal rights, conflict management in families, etc. Delivered by Rwanda Women's Network.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Village Savings and Loan Association (VSLA)
Description: A standard Village Savings and Loan Association program as run nationwide by CARE Rwanda.
Study: NCT00667368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Bi-monthly testing and treatment for BV with Metronidazole if BV is detected; 500mg twice daily for 7 days.
Study: NCT03923855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: BTL-899 therapy
Study: NCT01765205

Intervention type: DEVICE
Intervention: Pulse Oximetry using the INVOS (In Vivo Optical Spectroscopy) Cerebral/Somatic Oximeter
Description: Up to 50 healthy infants and up to 10 infants with CHD will receive the pulse oximetry using the INVOS Cerebral/Somatic Oximeter for 15 minutes to determine the effectiveness to measure somatic oxygen saturation. The pulse oximeter will be placed on the infants forehead with a hat and around the infants thigh to measure oxygen saturation.

Intervention type: DEVICE
Intervention: Pulse Oximetry using the INVOS (In Vivo Optical Spectroscopy) Cerebral/Somatic Oximeter
Description: Up to 50 healthy infants and up to 10 infants with CHD will receive the pulse oximetry using the INVOS Cerebral/Somatic Oximeter for 15 minutes to determine the effectiveness to measure somatic oxygen saturation. The pulse oximeter will be placed on the infants forehead with a hat and around the infants thigh to measure oxygen saturation.
Study: NCT00499876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mefloquine
Description: 250mg weekly PO for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tablet weekly PO for 6 months
Study: NCT03687489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Aortic Aneurysm Stent Graft System
Description: Abdominal aortic bifurcation stent and iliac artery extension stent were preloaded into abdominal aortic bifurcation stent transporter and iliac artery extension stent transporter, respectively. In the operation, the abdominal aorta bifurcation stent and the iliac artery extension stent will be delivered to the corresponding lesion position of the abdominal iliac artery and release. The abdominal aortic bifurcation stent and the iliac artery extension stent will form a whole through docking and thereby reducing the risk of rupture of an infrarenal abdominal aortic aneurysm due to the shock of blood flow.
Study: NCT02301494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.75% Imiquimod Cream
Description: CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% Fluocinonide Cream
Description: CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
Study: NCT02859207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).
Study: NCT01474057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DESTRESS-PC
Description: An online nurse-assisted, self-management intervention designed for primary care treatment of war-related PTSD, this intervention will consist of 3 weekly logins to a secure website for a period of 6 weeks. A DESTRESS Nurse will train the participant to use the website and will monitor their progress and report key information back to the primary care physician.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Usual Primary Care PTSD treatment
Description: Participants receive usual Primary Care treatment that is administered by the primary care physician; the DESTRESS Nurse monitors the participants' progress throughout the study.
Study: NCT03479268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT04692077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir (CAB) tablet
Description: 30 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet
Description: 300 mg/200 mg fixed-dose combination tablets
Study: NCT04087772

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Health Enhanced Positive Behavioral Interventions and Supports (PBIS-MH)
Description: Mental health-enhanced Positive Behavioral Interventions and Supports (PBIS-MH) integrates mental health into the three core elements of PBIS. 1) School-based mental health clinicians are included on leadership teams. 2) Data from teacher and student perceived school climate, as well as universal screening for aggression and mental health difficulties, are used to inform intervention decision-making. 3) Evidence-based mental health prevention and intervention practices are layered into PBIS' three-tiered continuum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Health Enhanced Positive Behavioral Interventions and Supports (PBIS-MH)
Description: Mental health-enhanced Positive Behavioral Interventions and Supports (PBIS-MH) integrates mental health into the three core elements of PBIS. 1) School-based mental health clinicians are included on leadership teams. 2) Data from teacher and student perceived school climate, as well as universal screening for aggression and mental health difficulties, are used to inform intervention decision-making. 3) Evidence-based mental health prevention and intervention practices are layered into PBIS' three-tiered continuum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Racial/Ethnic Discrimination Interventions (RED)
Description: Racial/Ethnic Discrimination Interventions are a set of components to address multiple forms of school-based racial and ethnic discrimination. 1) Unintentional bias training for school personnel, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias. 2) Unintentional bias training for students that is delivered in a classroom in a developmentally appropriate lesson format. 3) Vulnerable Decision Point process: Leadership teams are trained to reduce disparities in school discipline by a) using disaggregated student discipline data to identify particular settings or practices that are drivers for racial/ethnic disproportionality in a school and b) using iterative problem-solving to address these drivers. 4) Teacher stress reduction training where they are provided with strategies to reduce stress.